GSK Plc: Jemperli RUBY Phase III Trial Meets Primary Endpoin

LONDON (dpa-AFX) - GSK plc (GSK, GSK.L) reported positive headline results from the planned interim analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli

Related Keywords

London , City Of , United Kingdom , , More Such Health News , Jemperli , Ruby , Hase , Trial , Meets , Primary , Ndpoint ,